Description

PSMA-1007 (CAS 2226894-58-0) is a synthetic molecule designed as a precursor for radiolabeling in prostate cancer diagnostics. It targets Prostate-Specific Membrane Antigen (PSMA), a biomarker overexpressed in prostate cancer cells, enabling precise imaging in positron emission tomography (PET). PSMA-1007’s high purity (99.79%) and GMP manufacturing ensure consistent quality for research applications, particularly in the development of radiopharmaceuticals for cancer detection and therapy monitoring. This compound is essential in research advancing prostate cancer imaging agents and therapeutic approaches. Available for wholesale and retail distribution, PSMA-1007 is strictly for experimental laboratory use.

Product Specifications

Mechanism of Action & Research Applications

PSMA-1007 functions as a precursor for radiolabeled ligands targeting Prostate-Specific Membrane Antigen (PSMA), which is overexpressed on prostate cancer cells. Its binding specificity allows PET imaging agents to localize cancerous tissues effectively, facilitating early diagnosis, staging, and monitoring of prostate cancer progression. Research applications include development of novel radiopharmaceuticals and therapeutic monitoring. The compound’s GMP-grade quality supports reliable research outcomes.

Side Effects (For Reference Only)

PSMA-1007 is intended strictly for laboratory research and not for clinical use. No comprehensive toxicity or side effect profile in humans is available. Researchers should handle this compound according to standard safety protocols to minimize any potential exposure risks.

Disclaimer

This product is intended solely for laboratory research purposes. It is not approved for diagnostic or therapeutic use in humans or animals. Users must adhere to institutional guidelines and safety regulations during handling.